Introduction to Vertebral Artery Stenosis Treatment

Vertebral artery stenosis in the V1 segment significantly increases the risk of posterior circulation strokes. Clinicians traditionally use bare-metal stents (BMS) for endovascular intervention. However, recent advancements suggest that rapamycin-eluting stents (DES) might offer better long-term outcomes. A retrospective cohort study recently evaluated 191 patients to compare these two technologies directly.

Comparing Stent Performance and Safety

Researchers analyzed data from patients treated between January 2023 and August 2024. The cohort included 93 patients in the DES group and 98 in the BMS group. Initially, both groups showed similar baseline characteristics. The clinical team reported a high technical success rate for both stent types, exceeding 98%. Furthermore, the periprocedural safety profile remained excellent across the board. The 30-day stroke rate was just 1.1% for rapamycin-eluting stents compared to 2.0% for bare-metal stents. Consequently, the study confirmed that both procedures are safe for immediate clinical application.

Long-Term Efficacy of Rapamycin-Eluting Stents

The most significant findings emerged during the 12-month follow-up period. Kaplan-Meier survival analysis revealed that the DES group achieved a 94.5% patency rate. In contrast, the BMS group reached only 83.2%. Specifically, this difference was statistically significant, suggesting that drug-eluting technology effectively inhibits restenosis. Additionally, the DES group demonstrated a superior stroke-free survival rate of 97.8%, while the BMS group recorded 89.5%. These results indicate that DES provides better protection against recurrent ischemic events in the V1 segment. Therefore, clinicians should consider DES a more effective option for improving long-term patient outcomes in this specific anatomical location.

Clinical Implications for Practice

This study highlights that while perioperative safety is comparable, the drug-eluting coating provides a substantial advantage in preventing re-narrowing. Surgeons and neurologists should prioritize DES for V1 segment lesions to reduce the need for secondary interventions. However, the study authors note that further extended follow-up remains necessary to determine the long-term durability of these benefits.

Frequently Asked Questions

Why are rapamycin-eluting stents better than bare-metal stents?

Rapamycin-eluting stents release medication that prevents the overgrowth of tissue inside the stent. This process significantly reduces the risk of in-stent restenosis compared to traditional bare-metal stents.

Is the procedure for installing a DES more dangerous than a BMS?

No, this study found no significant difference in periprocedural complications or technical success rates. Both stent types showed a high safety profile during the first 30 days after the operation.

What is the primary benefit for patients choosing DES?

Patients receiving DES have a higher chance of the artery remaining open (patency) and a lower risk of experiencing a recurrent stroke within the first year of treatment.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Zhao KQ et al. [Efficacy and safety of rapamycin-eluting stents for vertebral artery stenosis in the V1 segment: a real-world retrospective cohort study]. Zhonghua Wai Ke Za Zhi. 2026 Mar 25. doi: 10.3760/cma.j.cn112139-20250820-00409. PMID: 41881799.

Zhang L et al. Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis. Front Neurol. 2021 Nov 25. doi: 10.3389/fneur.2021.748028.